<SEC-DOCUMENT>0000059478-20-000100.txt : 20200423
<SEC-HEADER>0000059478-20-000100.hdr.sgml : 20200423
<ACCEPTANCE-DATETIME>20200423080251
ACCESSION NUMBER:		0000059478-20-000100
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200423
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200423
DATE AS OF CHANGE:		20200423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		20809217

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>q12020earnings8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:a111b1a472f343f697b51e6a3ce834e4,x:f843273c46094819a5bf8ccc9d180c3e-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:lly="http://www.lilly.com/20200423" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q1Apr23" name="dei:AmendmentFlag" id="Fact-368D437F253A5BE29ED3BE40853484FE-wk-Fact-368D437F253A5BE29ED3BE40853484FE" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q1Apr23" name="dei:EntityCentralIndexKey" id="Fact-C7E6AED84DA25D66959A6E9CA195E99D-wk-Fact-C7E6AED84DA25D66959A6E9CA195E99D">0000059478</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="lly-20200423.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q1Apr23">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-23</xbrli:startDate>
			<xbrli:endDate>2020-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="s49B4071A59F05D9AB34AA1D9D6BA0E10"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;&#160;</span><span style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WASHINGTON, DC 20549&#160;</span></div><div style="line-height:174%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">________________</span></div><div style="line-height:120%;padding-top:17px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d1581210e84-wk-Fact-3305AC51ADD657BB90DA8B1EAA6CA995" name="dei:DocumentType" contextRef="D2020Q1Apr23"><span style="font-size:12pt;font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d) of the</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</span></div><div style="line-height:174%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">________________</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported): </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d1581210e110-wk-Fact-83B9855B698A565FBDA3F7987301AD4B" name="dei:DocumentPeriodEndDate" contextRef="D2020Q1Apr23" format="ixt:datemonthdayyearen">April 23, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:14pt;"><span><ix:nonNumeric id="d1581210e115-wk-Fact-A62E580AA82A5690B979710403D09FAF" name="dei:EntityRegistrantName" contextRef="D2020Q1Apr23"><span style="font-size:14pt;font-weight:bold;">ELI LILLY AND COMPANY</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:14pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> (Exact Name of Registrant as Specified in Charter)</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"><span><ix:nonNumeric id="d1581210e169-wk-Fact-2F8E3677682B58259BE1A209D95ADDC4" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q1Apr23" format="ixt-sec:stateprovnameen">Indiana</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"><span><ix:nonNumeric id="d1581210e179-wk-Fact-01A92A3FAD395760B6621B9D6CB81E33" name="dei:EntityFileNumber" contextRef="D2020Q1Apr23">001-06351</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"><span><ix:nonNumeric id="d1581210e189-wk-Fact-BC7A4061C42F5519B51E72373256FBFE" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q1Apr23">35-0470950</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or Other Jurisdiction</span></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of Incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Commission</span></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">File Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</span></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e255-wk-Fact-41E881BD7E165ACDA59958CBAB5982E7" name="dei:EntityAddressAddressLine1" contextRef="D2020Q1Apr23">Lilly Corporate Center</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e260-wk-Fact-804EFB3A2C745FB1B7096B915848035A" name="dei:EntityAddressCityOrTown" contextRef="D2020Q1Apr23">Indianapolis</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e264-wk-Fact-9AA511DAEDE7528593D0B74D7BBA7444" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q1Apr23" format="ixt-sec:stateprovnameen">Indiana</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e268-wk-Fact-8D3CCAE205005C7CAFF0607F0BDD0034" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q1Apr23">46285</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices, and Zip Code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e280-wk-Fact-BE58DE83EE365303B14251909C342A15" name="dei:CityAreaCode" contextRef="D2020Q1Apr23">317</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e284-wk-Fact-8079DF23051055478657DF0607341332" name="dei:LocalPhoneNumber" contextRef="D2020Q1Apr23">276-2000</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Registrant&#8217;s Telephone Number, Including Area Code</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not Applicable</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> (Former Name or Former Address, if Changed Since Last Report)</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:2px;text-align:center;"><hr></hr></div><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">see</span><span style="font-family:inherit;font-size:10pt;"> General Instruction A.2. below):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d1581210e325-wk-Fact-69D5F792AA455B2D800C3A091B632657" name="dei:WrittenCommunications" contextRef="D2020Q1Apr23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d1581210e350-wk-Fact-8AD8F7A9A4AA545A965FCB34CD29B00B" name="dei:SolicitingMaterial" contextRef="D2020Q1Apr23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d1581210e376-wk-Fact-2CDFF76871B1522994380231A0289A45" name="dei:PreCommencementTenderOffer" contextRef="D2020Q1Apr23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d1581210e402-wk-Fact-C0CEDD624684578A9B3C660780B93501" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q1Apr23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company </span><span><ix:nonNumeric id="d1581210e422-wk-Fact-9E26649FEDA0510F9759552CAD0A3EB4" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q1Apr23" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:30%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e470-wk-Fact-5FB55072CAFB58D6B81125EDC4344223" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">Common Stock (no par value)</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e475-wk-Fact-D94F262F9A3B5033A00FEA9602E4C019" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">LLY</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e480-wk-Fact-ECE184B819555081A016A8CF4383C6CC" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e486-wk-Fact-25323650B301534E8BA0C36606A1BF53" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member">1.000% Notes due 2022</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e491-wk-Fact-C755C99D10655EA9818CEC1B99641F29" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member">LLY22</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e496-wk-Fact-350F2FE285B157B48229B119B7F7566C" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e502-wk-Fact-13B9D95012BF51E3A93ADEE09A911912" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member">7 1/8% Notes due 2025</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e507-wk-Fact-3D85FB911A5E541C9E6961F54890FFF6" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member">LLY25</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e512-wk-Fact-1683AF99303050779B15AA62D1C26394" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e518-wk-Fact-AE50BFD9329557B2AC1C27590FEB98DA" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member">1.625% Notes due 2026</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e523-wk-Fact-03B15E5D07F2594CB0053ACBA593F255" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member">LLY26</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e528-wk-Fact-7271AFDDA64A5E5C90CC0537550C6A39" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e534-wk-Fact-07D4DC44B1FC53D58B63CE95F7DBF32B" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member">2.125% Notes due 2030</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e539-wk-Fact-3AC850390FA35A3392EA537405769EA3" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member">LLY30</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e544-wk-Fact-7E351F2D6D0855618AE4870845F05A19" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e550-wk-Fact-EE1882B7176559B9BC426C451014D115" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member">0.625% Notes due 2031</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e555-wk-Fact-BC96DDB680DC5E0B91D9CD0C918060C8" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member">LLY31</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e560-wk-Fact-F881DF53D1975C518E63AF663A0CABBD" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e566-wk-Fact-A247AD634CEA599681FC9065C87062DD" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member">6.77% Notes due 2036</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e571-wk-Fact-1BB19DA706A9549EB8F0877A24DA4A88" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member">LLY36</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e576-wk-Fact-2EAAE76CD681583385809063F5AE0CFE" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e582-wk-Fact-D11D264C96F45607ACAC0D97261A38CF" name="dei:Security12bTitle" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member">1.700% Notes due 2049</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e587-wk-Fact-028651DA85895049B663E28A1052C80B" name="dei:TradingSymbol" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member">LLY49A</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d1581210e592-wk-Fact-4B8702A425DA51A1B7BCB8F0904BA15D" name="dei:SecurityExchangeName" contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s62636d0889744ca19efb6431b3d131a5"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02.  </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Results of Operations and Financial Condition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated April 23, 2020, announcing our results of operations for the quarter ended March 31, 2020 (the &#8220;Reported Period&#8221;), including, among other things, unaudited operating results for that period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other Events</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information contained in Exhibit 99.1 (other than the quotes from David A. Ricks, our Chief Executive Officer, and Joshua Smiley, our Chief Financial Officer, our non-GAAP financial results for the Reported Period, our non-GAAP guidance and the reconciliations related thereto) is hereby incorporated by reference.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01.  </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Financial Statements and Exhibits</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit Number</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press release dated April 23, 2020, together with related attachments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:648px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:174px;"></td><td style="width:473px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="q120lillysalesandearningsp.htm"><span style="font-family:inherit;font-size:10pt;">99.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="q120lillysalesandearningsp.htm"><span style="font-family:inherit;font-size:10pt;">Press release dated April 23, 2020, together with related attachments</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ELI LILLY AND COMPANY</span></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant)</span></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Donald A. Zakrowski</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name:&#160;&#160;&#160;&#160;Donald A. Zakrowski</span></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title: &#160;&#160;&#160;&#160;Vice President, Finance and </span></div><div style="line-height:120%;text-align:left;padding-left:336px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Accounting Officer</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dated:  April 23, 2020</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q120lillysalesandearningsp.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2CA0F51232205930AB1968228A9B63CF"></a></div><div><div style="line-height:100%;text-align:right;"><img src="logoa31.jpg" alt="logoa31.jpg" style="height:70px;width:112px;"></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:54%;"></td><td style="width:21%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">April 23, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:10pt;font-weight:bold;">Eli Lilly and Company</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:8pt;">Lilly Corporate Center</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:8pt;">Indianapolis, Indiana  46285</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:8pt;">U.S.A. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:8pt;">+1.317.276.2000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:8pt;font-weight:bold;">www.lilly.com</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:12pt;font-weight:bold;">For Release:</font><font style="font-family:DIN-Regular,sans-serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">Immediately</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:DIN-Regular,sans-serif;font-size:12pt;font-weight:bold;">Refer to:</font><font style="font-family:DIN-Regular,sans-serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">&#160;&#160;&#160;&#160;Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media)</font></div><div style="line-height:100%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)</font></div><div style="line-height:140%;text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:140%;text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance</font></div><div style="line-height:140%;text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">Revenue in the first quarter of 2020 increased </font><font style="font-family:Garamond;font-size:12pt;font-style:italic;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">, driven by </font><font style="font-family:Garamond;font-size:12pt;font-style:italic;">22 percent</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#32;volume growth. Strong underlying demand for key growth products was augmented by approximately $250 million of additional revenue due to increased customer buying patterns and patient prescription trends due to the COVID-19 pandemic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">Key growth products launched since 2014, consisting of Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Basaglar, Tyvyt, Cyramza, and Baqsimi, contributed 19 percentage points of</font><font style="font-family:Garamond,serif;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">revenue growth and represented approximately </font><font style="font-family:Garamond;font-size:12pt;font-style:italic;">51 percent</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#32;of total revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">First-quarter 2020 operating expenses grew </font><font style="font-family:Garamond;font-size:12pt;font-style:italic;">7 percent</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">, driven by increased investments in R&amp;D.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">First-quarter 2020 earnings per share (EPS) decreased to </font><font style="font-family:Garamond;font-size:12pt;font-style:italic;">$1.60</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#32;on a reported basis, reflecting the gain recognized on the disposition of Elanco Animal Health in Q1 2019, and increased to </font><font style="font-family:Garamond;font-size:12pt;font-style:italic;">$1.75</font><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#32;on a non-GAAP basis. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">In response to the COVID-19 pandemic, Lilly has focused on reliably supplying medicines and has redirected scientific efforts to help solve critical issues, including researching potential therapeutics, and providing diagnostic and testing services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">Other notable recent events include new approved indications for Trulicity and Taltz, and the completion of the Dermira acquisition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">2020 EPS guidance adjusted to be in the range of $6.20 to $6.40 on a reported basis and $6.70 to $6.90 on a non-GAAP basis.</font></div></td></tr></table><div style="line-height:140%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:140%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #666666;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$ in millions, except </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">per share data</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;text-decoration:underline;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;text-decoration:underline;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;text-decoration:underline;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;text-decoration:underline;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;text-decoration:underline;">Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">5,859.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">5,092.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">15%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Net Income &#8211; Reported</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">1,456.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">4,241.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">(66)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">EPS &#8211; Reported</font></div><div style="padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div><div style="padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">1.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">4.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">(63)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Net Income &#8211; Non-GAAP</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">1,598.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">1,236.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">29%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">EPS &#8211; Non-GAAP</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">1.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">1.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">32%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP), include all revenue and expenses recognized during the periods, and reflect Elanco Animal Health (Elanco) as discontinued operations during 2019. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release, and assume that the disposition of Elanco occurred at the beginning of 2019 (including the benefit from the reduction in shares of common stock outstanding). The company&#8217;s 2020 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company&#8217;s business.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8220;Lilly is rising to meet the challenges of the COVID-19 pandemic, whether it be by supporting our employees, our communities, patients with chronic diseases who are the most vulnerable to the virus, or directly attacking the disease with new and existing therapies,&#8221; said David A. Ricks, Lilly&#8217;s chairman and CEO. &#8220;Lilly&#8217;s purpose - to make life better - has never been more important.&#160;We're focused on reliably supplying medicines, keeping&#160;our employees&#160;safe and pushing scientific efforts at top speed to defeat COVID-19.&#160;We're also committed to improving the affordability of and access to o</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">ur medicines, particularly insulin, during these challenging times."</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8220;Lilly exited 2019 with strong revenue growth and margin expansion, driven by the uptake of our newer medicines. That momentum continued in Q1 2020 and was augmented by higher patient and supply chain purchasing due to the COVID-19 pandemic," commented Josh Smiley, Lilly's CFO. "Our revenue and operating margin outlook for 2020 is unchanged, but the economic and healthcare consequences of this pandemic are uncertain and could negatively affect our financial results later in 2020 and beyond, due to reduced non-COVID healthcare activities and global economic challenges. We are therefore widening the range of our 2020 EPS guidance to reflect both our underlying strong performance as well as future uncertainty; however, the long-term fundamentals of our business remain strong, as does our financial outlook for the mid-2020s and beyond.&#8221;</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB5F6F678760957C0AE81129A0597DE2C"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:140%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Key Events Over the Last Three Months</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">COVID-19</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company entered into an agreement with the&#160;National Institute of Allergy and Infectious Diseases&#160;(NIAID), part of the&#160;National Institutes of Health, to study baricitinib as an arm in NIAID's Adaptive COVID-19 Treatment Trial. The Phase 3 study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company announced that it will advance LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2 (Ang2), to Phase 2 testing in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS).&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company entered into an agreement with AbCellera to co-develop antibody products for the potential treatment and prevention of COVID-19. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company announced an update on its clinical trial activities in light of the COVID-19 pandemic. The company has delayed most new study starts and has paused enrollment in most ongoing studies, but will continue ongoing clinical trials for patients who are already enrolled. </font></div></td></tr></table><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Regulatory</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The U.S. Food and Drug Administration (FDA) approved Trulicity</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">&#160;for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The FDA approved a supplemental Biologics License Application (sBLA) for Taltz</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">&#160;for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company's newest mealtime insulin received approval in both the European Union and </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;padding-left:48px;text-align:left;"><font style="font-family:Garamond,serif;font-size:12pt;">Japan for the treatment of adults with diabetes as part of a multiple daily injection regimen or delivered by an insulin pump. This&#160;novel, fast-acting formulation of insulin lispro is for use by adults with type 1 and type 2 diabetes to reduce blood glucose.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The FDA issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes. The letter indicates that the FDA is unable to approve the application in its current form.</font></div></td></tr></table><div style="line-height:180%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Clinical</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">An analysis performed by&#160;Washington University&#160;School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that solanezumab did not meet the primary endpoint of the study. At this time, Lilly does not plan to pursue a submission for solanezumab in people with dominantly inherited Alzheimer's disease (DIAD), also known as autosomal dominant Alzheimer's disease.&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company completed a Phase 4 study of Taltz in patients with moderate to severe psoriasis. Taltz demonstrated non-inferiority to guselkumab on the final secondary endpoint at week 24. As previously disclosed, Taltz achieved superiority compared to guselkumab on all primary and key secondary endpoints at week 12.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Mirikizumab met the co-primary and key secondary endpoints in a Phase 3, placebo-controlled study, which evaluated the safety and efficacy of mirikizumab for the treatment of moderate to severe plaque psoriasis over 52 weeks. A second Phase 3, placebo- and active- controlled 52-week study is expected to be completed later in 2020.</font></div></td></tr></table><div style="line-height:180%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Business Development/Other Developments</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company entered into an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">5</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;padding-left:48px;text-align:left;"><font style="font-family:Garamond,serif;font-size:12pt;">new medicines for autoimmune diseases.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company completed the acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, which is being evaluated in a Phase 3 clinical development program for the treatment of moderate to severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. The acquisition also expands Lilly's portfolio of marketed dermatology medicines with the addition of QBREXZA</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis.</font></div></td></tr></table><div style="line-height:180%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><a name="sEBF2C02FD14754ADBEE74E0342F8C3CF"></a></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">First-Quarter Reported Results</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">In the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, worldwide revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$5.860 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The increase in revenue was driven by a </font><font style="font-family:Garamond,serif;font-size:12pt;">22 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;increase due to volume, partially offset by a </font><font style="font-family:Garamond,serif;font-size:12pt;">6 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;decrease due to lower realized prices. The company estimates worldwide volume growth in the first quarter of 2020 was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased worldwide revenue by approximately $250 million.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Revenue in the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$3.329 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, as increased volume of </font><font style="font-family:Garamond,serif;font-size:12pt;">19 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;was partially offset by lower realized prices. Increased U.S. volume for key growth products, including Trulicity,</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;Taltz, Verzenio</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, Emgality, Basaglar</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, Jardiance</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, and Baqsimi</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, as well as for Humalog</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, was partially offset by decreased volume for Cialis</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;due to loss of patent exclusivity. The company estimates that U.S. volume growth in the first quarter of 2020 was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased U.S. revenue by approximately $200 million.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$2.531 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume of 25 percent, which was primarily from key growth products, including Tyvyt</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, Trulicity, Olumiant</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, Taltz, Jardiance, Verzenio, Cyramza</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;and Basaglar, as well as for Alimta</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, partially offset by decreased volume for Strattera</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;due to loss of patent exclusivity. The increase in revenue due to volume was </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. The company estimates that volume growth outside the U.S. in the first quarter of 2020 was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased revenue outside the U.S. by approximately $50 million.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Gross margin </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">18 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$4.645 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020 compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019 and was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic. Gross margin as a percent of revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">79.3 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">1.7</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;percentage points compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The increase in gross margin percent was primarily due to the prior year charges resulting from the withdrawal of Lartruvo</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:12pt;">, favorable product mix, and greater manufacturing efficiencies, partially offset by lower realized prices on revenue.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Total operating expenses in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, defined as the sum of research and development and marketing, selling, and administrative expenses, </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">7 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;to </font><font style="font-family:Garamond,serif;font-size:12pt;">$2.942 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. Research and development expenses </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">13 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;to </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.392 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, or </font><font style="font-family:Garamond,serif;font-size:12pt;">23.8 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;of revenue, driven by higher development expenses for late-stage assets. Marketing, selling, and administrative expenses </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">2 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;to </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.550 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">In the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, the company recognized acquired in-process research and development charges of </font><font style="font-family:Garamond,serif;font-size:12pt;">$52.3 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;related to the business development transaction with Sitryx. In</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;background-color:#ffffff;">the</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;background-color:#ffffff;">quarter of 2019, the company recognized acquired in-process research and development charges of</font><font style="font-family:Garamond,serif;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">$136.9 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">related to business development transactions with AC Immune SA and ImmuNext, Inc.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">In the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, the company recognized asset impairment, restructuring and other special charges of </font><font style="font-family:Garamond,serif;font-size:12pt;">$59.9 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. The charges were primarily related to acquisition and integration costs as part of the closing of the acquisition of Dermira. In the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019, the company recognized asset impairment, restructuring and other special charges of </font><font style="font-family:Garamond,serif;font-size:12pt;">$423.9 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">associated with accelerated vesting of Loxo Oncology employee equity awards as part of the closing of the acquisition of Loxo Oncology.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Operating income in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020 was </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.591 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, compared to </font><font style="font-family:Garamond,serif;font-size:12pt;">$645.1 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The increase in operating income was primarily driven by higher gross margin and lower asset impairment, restructuring and other special charges and acquired in-process research and development charges, partially offset by higher research and development expenses.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Other income was </font><font style="font-family:Garamond,serif;font-size:12pt;">$89.1 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, compared with </font><font style="font-family:Garamond,serif;font-size:12pt;">$86.0 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The increase in other income was driven primarily by higher net gains on investment securities, partially offset by lower interest income. The higher net gains on investments were due primarily to increased market valuations of two companies in Lilly's investment portfolio that are currently developing potential vaccines against COVID-19.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The effective tax rate was </font><font style="font-family:Garamond,serif;font-size:12pt;">13.3 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, compared with </font><font style="font-family:Garamond,serif;font-size:12pt;">23.3 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The higher effective tax rate in the first quarter of 2019 was primarily due to the non-deductibility of the accelerated vesting of Loxo Oncology employee equity awards as part of the closing of the acquisition of Loxo Oncology, as well as tax expenses associated with the withdrawal of Lartruvo.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">In the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, net income and earnings per share were </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.457&#160;billion</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;and </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.60</font><font style="font-family:Garamond,serif;font-size:12pt;">, respectively, compared with net income of </font><font style="font-family:Garamond,serif;font-size:12pt;">$4.242&#160;billion</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;and earnings per share of </font><font style="font-family:Garamond,serif;font-size:12pt;">$4.31</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The decrease in net income and earnings per share in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020 was primarily driven by the $3.681 billion gain recognized on the disposition of Elanco in the first quarter of 2019, partially offset by higher operating income in 2020. Earnings per share in the first quarter of 2020 benefited from lower weighted-average shares outstanding as a result of the Elanco exchange offer.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">8</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s19279CE0BE5F56E5BFD2B88AF57E7BC7"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">First-Quarter Non-GAAP Measures</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">On a non-GAAP basis, </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">-quarter 2020 gross margin </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$4.703 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019 and was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic. Gross margin as a percent of revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">80.3 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">0.1</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;percentage points. The increase in gross margin percent was primarily due to favorable product mix and manufacturing efficiencies, offset by the impact of lower realized prices on revenue.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Operating income on a non-GAAP basis </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">$427.5 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, or </font><font style="font-family:Garamond,serif;font-size:12pt;">32</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;percent, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.762 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020 compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019, due to higher gross margin, partially offset by higher research and development expenses. </font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The effective tax rate on a non-GAAP basis was </font><font style="font-family:Garamond,serif;font-size:12pt;">13.6 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, compared with </font><font style="font-family:Garamond,serif;font-size:12pt;">12.9 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The higher effective tax rate for the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020 was driven primarily by a mix of earnings in higher tax jurisdictions, partially offset by an increase in net discrete tax benefits.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">On a non-GAAP basis, in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020 net income </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">29 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.599 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, while earnings per share increased </font><font style="font-family:Garamond,serif;font-size:12pt;">32 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.75</font><font style="font-family:Garamond,serif;font-size:12pt;">, compared with </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.237 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;and </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.33</font><font style="font-family:Garamond,serif;font-size:12pt;">, respectively, in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2019. The increase in net income and earnings per share was driven primarily by higher operating income, partially offset by higher income taxes.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For further detail of non-GAAP measures, see the reconciliation below as well as the "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information" table later in this press release.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">First Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Earnings per share (reported)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">1.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">4.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">(63)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">(3.74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Earnings per share from continuing operations (reported)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">1.60</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">0.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Lartruvo charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Impact of reduced shares outstanding for non-GAAP reporting</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Earnings per share (non-GAAP)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">1.75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">1.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">32%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:Garamond,serif;font-size:8pt;">Numbers may not add due to rounding.</font></div><div style="font-size:8pt;"><font style="font-family:Garamond,serif;font-size:8pt;">(a) Non-GAAP earnings per share assume that the disposition of Elanco occurred at the beginning of 2019 and, therefore, exclude the approximately 65.0 million shares of Lilly common stock retired in the Elanco exchange offer.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">10</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s685F1135EA4A5B95A6801C1BFA3D2A12"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.490566037735846%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:19%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;padding-left:1px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Selected Revenue Highlights</font></div><div style="padding-top:1px;padding-left:1px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-style:italic;">(Dollars in millions)</font></div></td><td colspan="9" style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">First Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Selected Products</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;padding-left:1px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Trulicity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">1,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">879.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">40%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Humalog</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">695.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">730.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">(5)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Alimta</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">560.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">499.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">12%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Taltz</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">443.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">252.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">76%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Humulin</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">315.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">297.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Basaglar</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">303.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">251.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">21%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Forteo</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">272.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">312.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">(13)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Jardiance</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">267.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">203.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">31%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Cyramza</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">239.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">198.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">21%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Cymbalta</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">210.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">164.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">28%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Verzenio</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">188.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">109.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">72%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Olumiant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">139.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">82.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">70%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Emgality</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">74.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">14.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">NM</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Tyvyt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">57.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">9.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">NM</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Baqsimi</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">17.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">NM</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Total Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">5,859.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">5,092.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#160;Humalog includes Insulin Lispro</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#160;Jardiance includes Glyxambi</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;,</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#160;Synjardy</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">, and Trijardy</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#160;XR</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM &#8211; not meaningful; Numbers may not add due to rounding</font></div></td></tr></table></div></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">11</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Impact of COVID-19 on First-Quarter 2020 Revenue</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company estimates that revenue in the first quarter of 2020 for many of its products was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased revenue by approximately $250 million worldwide, including approximately $200 million in the U.S. and approximately $50 million outside the U.S. The company believes that the increase in U.S. revenue from COVID-19 primarily impacted its portfolio of diabetes medicines, with estimated increases of approximately $70 million to $80 million for insulin products and approximately $30 million to $40 million for Trulicity.&#160; The company also estimates that U.S. revenue for Taltz was favorably impacted by approximately $20 million to $25 million.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Trulicity</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">First-quarter 2020 worldwide Trulicity revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$1.229 billion</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">40 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue increased </font><font style="font-family:Garamond,serif;font-size:12pt;">40 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$929.5 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume, partially offset by lower realized prices. Trulicity's lower realized prices in the U.S. were primarily due to higher contracted rebates and changes in segment mix, partially offset by higher list prices. Revenue outside the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$299.9 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">40 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Humalog</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Humalog revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">decreased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">5 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$695.8 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. Revenue in the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">decreased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">11 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$398.6 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven primarily by lower realized prices due to changes in estimates for rebates and discounts and changes in segment mix, partially offset by increased volume. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">5 </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$297.2 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Alimta</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Alimta revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">12 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$560.1 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$324.2&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume and, to a lesser extent, higher realized prices. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">8 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;to </font><font style="font-family:Garamond,serif;font-size:12pt;">$235.8 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume, partially offset by lower realized prices and, to a lesser extent, the unfavorable impact of foreign exchange rates.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Taltz</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Taltz revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">76 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$443.5&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">81 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$327.5&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume and, to a lesser extent, higher realized prices primarily due to changes in estimates for rebates and discounts. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">62 percent</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Garamond,serif;font-size:12pt;">to </font><font style="font-family:Garamond,serif;font-size:12pt;">$116.0 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Humulin</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Humulin revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">6 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$315.7 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">6 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$214.1 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume, partially offset by lower realized prices due to changes in segment mix. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">5 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$101.5 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, due to increased volume and, to a lesser extent, higher realized prices, partially offset by the unfavorable impact of foreign exchange rates.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Basaglar</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Basaglar revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">21 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$303.7 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">16 percent</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;to </font><font style="font-family:Garamond,serif;font-size:12pt;">$230.4 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">13</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">driven by increased volume. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">38 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$73.3&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. Basaglar is part of the company&#8217;s alliance with Boehringer Ingelheim. Lilly reports as cost of sales payments made to Boehringer Ingelheim for royalties and for its portion of the gross margin in 2020 and 2019, respectively.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Forteo</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Forteo revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">decreased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">13 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$272.4 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">decreased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">3 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$122.5 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by lower realized prices primarily due to the unfavorable impact of higher contracted rates. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">decreased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">20 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;to </font><font style="font-family:Garamond,serif;font-size:12pt;">$149.8&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by decreased volume and, to a lesser extent, lower realized prices. </font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company expects further volume declines for Forteo as a result of competitive dynamics in the U.S. and the entry of generic and biosimilar competition following the loss of patent exclusivity in the third quarter of 2019 in the U.S., Japan and major European markets.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Jardiance</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company&#8217;s worldwide Jardiance revenue during the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;was </font><font style="font-family:Garamond,serif;font-size:12pt;">$267.5 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">31 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue increased </font><font style="font-family:Garamond,serif;font-size:12pt;">15 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$144.6 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume. Revenue outside the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$122.9 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">57 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume. Jardiance is part of the company&#8217;s alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance and its portion of Jardiance&#8217;s gross margin in 2020 and 2019, respectively.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Cyramza</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Cyramza revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$239.0&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">21 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$89.1&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">19 </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">14</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume. Revenue outside the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$149.9&#160;million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">22 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Cymbalta</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Cymbalta revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">28 percent</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$210.4 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter. Revenue outside the U.S. </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">29 percent</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">to </font><font style="font-family:Garamond,serif;font-size:12pt;">$198.8 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume, partially offset by lower realized prices. The increase in volume outside the U.S. was primarily driven by the company&#8217;s sale of its rights for Xeristar in Spain.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Verzenio</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, worldwide Verzenio revenue </font><font style="font-family:Garamond,serif;font-size:12pt;">increased</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;</font><font style="font-family:Garamond,serif;font-size:12pt;">72 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, to </font><font style="font-family:Garamond,serif;font-size:12pt;">$188.0 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$129.4 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">38 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">, primarily driven by increased volume. Revenue outside the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$58.6 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">$42.7 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;driven by increased volume.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Olumiant</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2020</font><font style="font-family:Garamond,serif;font-size:12pt;">, Olumiant generated worldwide revenue of </font><font style="font-family:Garamond,serif;font-size:12pt;">$139.7 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S. revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$11.3 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. Revenue outside the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$128.4 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">70 percent</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of </font><font style="font-family:Garamond,serif;font-size:12pt;">2019</font><font style="font-family:Garamond,serif;font-size:12pt;">, driven by increased volume. </font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Emgality</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020, Emgality generated worldwide revenue of </font><font style="font-family:Garamond,serif;font-size:12pt;">$74.0 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">$7.8 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the fourth quarter of 2019. U.S. revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$67.3 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">$4.2 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the fourth quarter of 2019, primarily driven by increased volume, partially offset by lower realized prices due to changes to estimates in rebates and discounts. Revenue outside of the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$6.7 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;in the </font><font style="font-family:Garamond,serif;font-size:12pt;">first</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;quarter of 2020.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">15</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Tyvyt</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company's Tyvyt revenue during the first quarter of 2020 was </font><font style="font-family:Garamond,serif;font-size:12pt;">$57.4 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, an increase of </font><font style="font-family:Garamond,serif;font-size:12pt;">$20.0 million</font><font style="font-family:Garamond,serif;font-size:12pt;">&#32;compared with the fourth quarter of 2019. Tyvyt is part of the company&#8217;s alliance with Innovent Biologics, Inc. in China. Lilly reports total sales of Tyvyt made by Lilly as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. Lilly also reports as revenue a portion of the gross margin for Tyvyt sales made by Innovent.&#160; </font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Baqsimi</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">For the first quarter of 2020, Baqsimi generated worldwide revenue of </font><font style="font-family:Garamond,serif;font-size:12pt;">$17.8 million</font><font style="font-family:Garamond,serif;font-size:12pt;">. U.S revenue was </font><font style="font-family:Garamond,serif;font-size:12pt;">$15.8 million</font><font style="font-family:Garamond,serif;font-size:12pt;">, while revenue outside the U.S. was </font><font style="font-family:Garamond,serif;font-size:12pt;">$2.0 million</font><font style="font-family:Garamond,serif;font-size:12pt;">.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">16</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sDF6B08260057543687B453A852AE5CBB"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">2020 Financial Guidance</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company has updated certain elements of its 2020 financial guidance on a reported basis and a non-GAAP basis to reflect both management's expectations for operational performance and the uncertainty surrounding the extent and duration of the impact of the COVID-19 pandemic. Key management assumptions supporting the updated guidance include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The increased customer buying patterns and patient prescription trends associated with COVID-19 that were experienced in the first quarter of 2020 will largely be reversed over the course of 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The reduction in new-to-brand prescription trends will peak in the second quarter of 2020 in the U.S. and much of Europe;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Healthcare activity, including non-COVID-19 related patient visits with their physicians, will align more closely with historical levels in the second half of 2020; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Increased utilization of patient affordability programs and changes in segment mix due to increased U.S. unemployment will negatively impact U.S. pricing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Clinical trial enrollment in existing studies, as well as initiation of new clinical trials, will resume in the second half of 2020; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Investment in COVID-19 related research, testing and support will continue throughout 2020.</font></div></td></tr></table><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Based on the key assumptions outlined above, the company has adjusted earnings per share for 2020 to now be in the range of $6.20 to $6.40 on a reported basis and $6.70 to $6.90 on a non-GAAP basis.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">17</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.16142557651992%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:64%;"></td><td style="width:18%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">2020</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Expectations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">% Change from 2019</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Earnings per share (reported)</font><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">$6.20 to $6.40</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">25% to 29%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Amortization of intangible assets</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Acquired IPR&amp;D</font><font style="font-family:Garamond,serif;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Asset impairment, restructuring and other special charges</font></div><div style="font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">.06</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Earnings per share (non-GAAP)</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">$6.70 to $6.90</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">11% to 14%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Garamond,serif;font-size:8pt;">Numbers may not add due to rounding</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Garamond,serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font><font style="font-family:Garamond,serif;font-size:8pt;">&#160;Reported earnings per share percent change from 2019 calculated based on change from 2019 earnings per share from continuing operations.</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Garamond,serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></font><font style="font-family:Garamond,serif;font-size:8pt;">&#160;Includes upfront payments for acquired in-process research and development transactions with Sitryx and AbCellera</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Garamond,serif;font-size:8pt;">.</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The company still anticipates 2020 revenue between $23.7 billion and $24.2 billion. Revenue growth is still expected to be driven by volume from key growth products including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, Emgality, Baqsimi and Tyvyt, as well as the addition of QBREXZA revenue and the potential launch of other new medicines. Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity. Revenue growth is also expected to be partially offset by a low-single digit net price decline in the U.S. driven primarily by rebates and legislated increases to Medicare Part D cost sharing, patient affordability programs, and net price declines in China, Japan and Europe. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Gross margin as a percent of revenue is still expected to be approximately 79.0 percent on a reported basis and approximately 81.0 percent on a non-GAAP basis. </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Marketing, selling and administrative expenses are still expected to be in the range of $6.2 billion to $6.4 billion. Research and development expenses are still expected to be in the range of $5.6 billion to $5.9 billion. </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Operating margin percentage, defined as operating income as a percent of revenue, is still expected to be approximately 28 percent on a reported basis and 31 percent on a non-GAAP basis.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Other income (expense) is now expected to be in the range of $0 to $150 million of expense.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The 2020 effective tax rate is still expected to be approximately 15 percent on both a reported basis and a non-GAAP basis.</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">The following table summarizes the company&#8217;s 2020 financial guidance: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:26%;"></td><td style="width:2%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">2020 Guidance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Prior</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;text-decoration:underline;">Updated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$23.7 to $24.2 billion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Gross Margin % of Revenue (reported)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Approx. 79%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Gross Margin % of Revenue (non-GAAP)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Approx. 81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Marketing, Selling &amp; Administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$6.2 to $6.4 billion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Research &amp; Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$5.6 to $5.9 billion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Other Income/(Expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$(250) to $(100) million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$(150) to $0 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Tax Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Approx. 15%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Earnings per share (reported)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$6.18 to $6.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$6.20 to $6.40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Earnings per share (non-GAAP)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$6.70 to $6.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">$6.70 to $6.90</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Operating Income % of Revenue (reported)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">28%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Operating Income % of Revenue (non-GAAP)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">31%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Unchanged</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Non-GAAP guidance reflects adjustments presented in the earnings per share table above.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">19</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s813DD689FB485432A56C1BE0AF8AD0C7"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;font-weight:bold;">Webcast of Conference Call</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">As previously announced, investors and the general public can access a live webcast of the first-quarter 2020 financial results conference call through a link on Lilly&#8217;s website at www.lilly.com. The conference call will begin at 9:00 a.m. Eastern time (ET) today and will be available for replay via the website.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;">Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. F-LLY</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:Garamond,serif;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">This press release contains management&#8217;s current intentions and expectations for the future, all of which are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;intend&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221;, &#8220;target&#8221;, &#8220;anticipate&#8221; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees that pipeline products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company&#8217;s results may also be affected by such factors as the timing of anticipated regulatory approvals and launches of new products; market uptake of recently launched products; competitive developments affecting current products and our pipeline; the expiration of intellectual property protection for certain of the company&#8217;s products; the company&#8217;s ability to protect and enforce patents and other intellectual property; the impact of actions of governmental and private payers affecting the pricing of, reimbursement for, and access to pharmaceuticals; regulatory compliance problems or government investigations; regulatory actions regarding currently marketed products; unexpected safety or efficacy concerns associated with the company&#8217;s products; issues with product supply stemming from manufacturing difficulties or disruptions; regulatory changes or other developments; changes in patent law or regulations related to data-package exclusivity; litigation involving past, current or future products; unauthorized disclosure, misappropriation, or compromise of trade secrets or other confidential data stored in the company&#8217;s information systems, networks and facilities, or those of third parties with which the company shares its data; changes in tax law and regulations, including the impact of U.S. tax reform legislation enacted in December 2017 and related guidance; changes in inflation, interest rates, and foreign currency exchange rates; asset impairments and restructuring charges; changes in accounting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); acquisitions and business development transactions and related integration costs; information technology system inadequacies or operating failures; the impact of the evolving COVID-19 pandemic, and the global response thereto; reliance on third-party relationships and outsourcing arrangements; and global macroeconomic conditions. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company&#8217;s latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is require</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">d by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Alimta</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(pemetrexed disodium, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Baqsimi&#8482; (glucagon, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Basaglar</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(insulin glargine injection, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cialis</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(tadalafil, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cymbalta</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(duloxetine, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cyramza</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(ramucirumab, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Emgality</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(galcanezumab-gnlm, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Forteo</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(teriparatide of recombinant DNA origin injection, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Glyxambi</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(empagliflozin/linagliptin, Boehringer Ingelheim)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Humalog</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Humulin</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(human insulin of recombinant DNA origin, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Jardiance</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Garamond,serif;font-size:10pt;">(empagliflozin, Boehringer Ingelheim)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Lartruvo</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(olaratumab, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Olumiant</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(baricitinib, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">QBREXZA</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(Glycopyrronium cloth, Dermira)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Strattera</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(atomoxetine, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Synjardy</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(empagliflozin/metformin, Boehringer Ingelheim)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Taltz</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Garamond,serif;font-size:10pt;">(ixekizumab, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Trijardy</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8482;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Trulicity</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Garamond,serif;font-size:10pt;">(dulaglutide, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Tyvyt</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(sintilimab injection, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Verzenio</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;(abemaciclib, Lilly)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Third party trademarks used herein are trademarks of their respective owners.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:329px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Eli Lilly and Company Employment Information</font></div></td></tr></table></div></div><div style="line-height:180%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:18%;"></td><td style="width:17%;"></td><td style="width:23%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;text-decoration:underline;">March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;text-decoration:underline;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Worldwide Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">33,815</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">33,755</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Garamond,serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">21</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sAF7C0C2A5E9E5530B62003E9A429FF94"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.34146341463415%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Eli Lilly and Company</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Operating Results  (Unaudited) &#8211; REPORTED</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(Dollars in millions, except per share data)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.70731707317073%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:2%;"></td><td style="width:3%;"></td><td style="width:3%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:2%;"></td><td style="width:2%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Three Months Ended</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">March 31,</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">2019</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">% Chg.</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">5,859.8</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">5,092.2</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">15%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,215.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,138.7</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">7%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,392.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,230.5</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">13%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Marketing, selling and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,549.6</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,517.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">2%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">52.3</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">136.9</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(62)%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Asset impairment, restructuring and other special charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">59.9</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">423.9</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(86)%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Operating income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,590.8</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">645.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net interest income (expense)</font></div><div style="padding-left:12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(78.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(55.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net other income (expense)</font></div><div style="padding-left:12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">167.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">141.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">89.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">4%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,679.9</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">731.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">223.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">170.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">31%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,456.5</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">561.1</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income from discontinued operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">3,680.5</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,456.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">4,241.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(66)%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Earnings from continuing operations - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Earnings from discontinued operations - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">3.74</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Earnings per share - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">4.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(63)%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Dividends paid per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.7400</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.6450</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">15%</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">911,713</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">984,001</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">NM &#8211; not meaningful</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s9B4C713B22CA59F59EE73EEDF84A4345"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:22%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="16" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Eli Lilly and Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="16" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="16" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(Dollars in millions, except per share data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="16" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Three Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Three Months Ended<br>March 31, 2019</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">GAAP Reported</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Adjustments</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Non-GAAP Adjusted</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">GAAP Reported</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Adjustments</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Non-GAAP Adjusted</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">1,215.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(58.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,156.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">1,138.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(128.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,010.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">52.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(52.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">136.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(136.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Asset impairment, restructuring and other special charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">59.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(59.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">423.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(423.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">223.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">251.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">170.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">13.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">183.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">1,456.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">142.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,598.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">561.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">675.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,236.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income from discontinued operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">3,680.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(3,680.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">1,456.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">142.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,598.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">4,241.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(3,004.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1,236.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Earnings per share - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">1.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">4.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(2.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">1.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">911,713</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">911,713</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">984,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(54,167</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">929,834</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">The table above reflects only line items with non-GAAP adjustments.&#160;</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company&#8217;s non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company&#8217;s reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company&#8217;s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:4px;text-align:left;"><font style="font-family:Garamond,serif;font-size:10pt;">Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Adjustments to certain GAAP reported measures for the three months ended March 31, 2020, include the following: </font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(Dollars in millions, except per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Amortization </font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(i)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">IPR&amp;D</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(ii)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Other specified items</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(iii)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(54.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(4.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(58.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(52.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(52.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(59.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(59.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">11.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">11.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">28.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">41.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">142.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Earnings per share - diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">0.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:48px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">The table above reflects only line items with non-GAAP adjustments.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to a business development transaction with Sitryx.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Asset impairment, restructuring and other special charges exclude primarily acquisition and integration costs as part of the closing of the acquisition of Dermira.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">24</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #666666;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Garamond,serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Adjustments to certain GAAP reported measures for the three months ended March 31, 2019, include the following:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.45283018867924%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(Dollars in millions, except per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Amortization </font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(i)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">IPR&amp;D </font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(ii)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Other specified items</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(iii)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Reduced shares outstanding</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(iv)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Lartruvo charges </font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(v)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Discontinued operations</font><font style="font-family:Garamond,serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(vi)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(43.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(84.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(128.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(136.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(136.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(411.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(12.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(423.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">28.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">13.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">108.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">407.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(3,680.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(3,004.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Earnings per share - diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">(3.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">(2.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:48px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to business development transactions with AC Immune SA and ImmuNext, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude charges primarily associated with the accelerated vesting of Loxo Oncology employee equity awards as part of the closing of the acquisition of Loxo Oncology.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">iv.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Non-GAAP earnings per share assume that the disposition of Elanco occurred at the beginning of 2019 and therefore include the benefit from the reduction in shares of common stock outstanding.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">v.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude charges related to the withdrawal of Lartruvo.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Garamond,serif;font-size:10pt;">vi.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">Exclude discontinued operations of Elanco.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:14px;border-top:1px solid #666666;"><div style="padding-top:8px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">25</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20200423.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20200423" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20200423" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20200423_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20200423_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20200423_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20200423_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="lly_A1.000NotesDueJune22022Member" name="A1.000NotesDueJune22022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lly_A1.625NotesDueJune22026Member" name="A1.625NotesDueJune22026Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lly_A1.700Notesdue2049Member" name="A1.700Notesdue2049Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lly_A2.125NotesDueJune32030Member" name="A2.125NotesDueJune32030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lly_A6.77NotesDueJanuary12036Member" name="A6.77NotesDueJanuary12036Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lly_A625Notesdue2031Member" name="A625Notesdue2031Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lly_A718NotesDueJune12025Member" name="A718NotesDueJune12025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>lly-20200423_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:href="lly-20200423.xsd#CoverPage" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>lly-20200423_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:href="lly-20200423.xsd#CoverPage" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E97C91817128B49464B01409D58742D3_72A7D94D1060500688F393608F245A59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:to="loc_us-gaap_ClassOfStockDomain_E97C91817128B49464B01409D58742D3_72A7D94D1060500688F393608F245A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:to="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.000NotesDueJune22022Member" xlink:label="loc_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A718NotesDueJune12025Member" xlink:label="loc_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.625NotesDueJune22026Member" xlink:label="loc_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A2.125NotesDueJune32030Member" xlink:label="loc_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A625Notesdue2031Member" xlink:label="loc_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A6.77NotesDueJanuary12036Member" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.700Notesdue2049Member" xlink:label="loc_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lly-20200423_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_CoverAbstract_0C2F5F336E3F402245681409D587878C_label_en-US" xlink:label="lab_dei_CoverAbstract_E29A61F1FEE251F4951347B68CD0DAD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_E29A61F1FEE251F4951347B68CD0DAD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_E29A61F1FEE251F4951347B68CD0DAD2" xlink:to="lab_dei_CoverAbstract_E29A61F1FEE251F4951347B68CD0DAD2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationTable_387AA92958996E3918A91409D58720CF_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_387AA92958996E3918A91409D58720CF_label_en-US" xlink:label="lab_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:to="lab_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E499AE70C3F0771CACDB1409D5876BC7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E499AE70C3F0771CACDB1409D5876BC7_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:to="lab_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_E97C91817128B49464B01409D58742D3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_E97C91817128B49464B01409D58742D3_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="lab_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonClassAMember_D1E13A6400885BA3D4C81409D5887A88_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_D1E13A6400885BA3D4C81409D5887A88_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:to="lab_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:type="arc" />
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_0F037473006239E4737B1409D58884A8_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_0F037473006239E4737B1409D58884A8_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_0F037473006239E4737B1409D58884A8_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.000NotesDueJune22022Member" xlink:label="loc_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:to="lab_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:type="arc" />
    <link:label id="lab_lly_A718NotesDueJune12025Member_CB9E8918422AD53AD9FC1409D5884E9C_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_CB9E8918422AD53AD9FC1409D5884E9C_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">7 1/8% Notes Due June 1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_CB9E8918422AD53AD9FC1409D5884E9C_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">7 1/8% Notes Due June 1, 2025 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A718NotesDueJune12025Member" xlink:label="loc_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:to="lab_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:type="arc" />
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_CB16A6376A06FC26EE8D1409D588C6D5_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_CB16A6376A06FC26EE8D1409D588C6D5_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_CB16A6376A06FC26EE8D1409D588C6D5_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.625NotesDueJune22026Member" xlink:label="loc_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:to="lab_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:type="arc" />
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_B7210C2D988FF9727B7D1409D5892492_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_B7210C2D988FF9727B7D1409D5892492_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_B7210C2D988FF9727B7D1409D5892492_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A2.125NotesDueJune32030Member" xlink:label="loc_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:to="lab_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:type="arc" />
    <link:label id="lab_lly_A625Notesdue2031Member_8C731CBD8F09CF4C78441409D589161A_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_8C731CBD8F09CF4C78441409D589161A_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_8C731CBD8F09CF4C78441409D589161A_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A625Notesdue2031Member" xlink:label="loc_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:to="lab_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:type="arc" />
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_C83363ED7ED7938471AB1409D5894F1E_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_C83363ED7ED7938471AB1409D5894F1E_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.77% Notes Due January 1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_C83363ED7ED7938471AB1409D5894F1E_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.77% Notes Due January 1, 2036 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A6.77NotesDueJanuary12036Member" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:type="arc" />
    <link:label id="lab_lly_A1.700Notesdue2049Member_6179757C23479821D4A71409D5891B86_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_6179757C23479821D4A71409D5891B86_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_6179757C23479821D4A71409D5891B86_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.700Notesdue2049Member" xlink:label="loc_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:to="lab_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_A6FDD5BB81EF639304B81409D5890DB1_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_A6FDD5BB81EF639304B81409D5890DB1_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="lab_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_4509993ED51DEE2730171409D5892509_terseLabel_en-US" xlink:label="lab_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_4509993ED51DEE2730171409D5892509_label_en-US" xlink:label="lab_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:to="lab_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_CD7E5C19A61258D55F401409D58A24C0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_CD7E5C19A61258D55F401409D58A24C0_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:to="lab_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_DCDACB45B7BDDB9BC8BD1409D58A41E8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_DCDACB45B7BDDB9BC8BD1409D58A41E8_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:to="lab_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_7021990ABAC1C3AAF5691409D58AD608_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_7021990ABAC1C3AAF5691409D58AD608_label_en-US" xlink:label="lab_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:to="lab_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_EBDFA87701059BB02C2E1409D58A89D6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_EBDFA87701059BB02C2E1409D58A89D6_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:to="lab_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_A4D6A99BA4BCB98C2CC81409D58B1A66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_A4D6A99BA4BCB98C2CC81409D58B1A66_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:to="lab_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_F5D8BC01B987697023021409D58B87AA_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_F5D8BC01B987697023021409D58B87AA_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:to="lab_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_A817453A9E7D0354C6A91409D58B87BB_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_A817453A9E7D0354C6A91409D58B87BB_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:to="lab_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_368DE07C69C0F2904FB41409D58C350F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_368DE07C69C0F2904FB41409D58C350F_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:to="lab_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_996B8DE6856179F5D38B1409D58C4889_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_996B8DE6856179F5D38B1409D58C4889_label_en-US" xlink:label="lab_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:to="lab_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_C4EABBFE117A0DF560F41409D58C5DC8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_C4EABBFE117A0DF560F41409D58C5DC8_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:to="lab_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_168365789BD07A8B1F571409D58C1947_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_168365789BD07A8B1F571409D58C1947_label_en-US" xlink:label="lab_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:to="lab_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_9233FE2177BAB20687681409D58C97DB_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_9233FE2177BAB20687681409D58C97DB_label_en-US" xlink:label="lab_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:to="lab_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_F1728B08B2A0ADDEF4CD1409D58C95A1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_F1728B08B2A0ADDEF4CD1409D58C95A1_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:to="lab_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_78BFD0782F4E9B7396BC1409D58CB80F_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_78BFD0782F4E9B7396BC1409D58CB80F_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_889161516359C72669491409D58CC7D1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_889161516359C72669491409D58CC7D1_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:to="lab_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_FA41708333D24B8A93A81409D58C2C22_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_FA41708333D24B8A93A81409D58C2C22_label_en-US" xlink:label="lab_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:to="lab_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_1F24D0534302D5D706041409D58D1A67_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_1F24D0534302D5D706041409D58D1A67_label_en-US" xlink:label="lab_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:to="lab_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_FB6D3C0001C63000850D1409D58D70CD_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_FB6D3C0001C63000850D1409D58D70CD_label_en-US" xlink:label="lab_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:to="lab_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_E2C063252473E37AA7461409D58D7974_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_E2C063252473E37AA7461409D58D7974_label_en-US" xlink:label="lab_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:to="lab_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_B9AA1E727B5607BC57EA1409D58E7602_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_B9AA1E727B5607BC57EA1409D58E7602_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:to="lab_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_4AEDABBCC4FA15981C9E1409D58F2A5B_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_4AEDABBCC4FA15981C9E1409D58F2A5B_label_en-US" xlink:label="lab_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:to="lab_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lly-20200423_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:href="lly-20200423.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_E29A61F1FEE251F4951347B68CD0DAD2" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_E29A61F1FEE251F4951347B68CD0DAD2" xlink:to="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_81C3A731E82456FE8E044787AD2F8CFF" xlink:to="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_us-gaap_CommonClassAMember_A3BCA3623B37543F99C2B9A5DD680216" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.000NotesDueJune22022Member" xlink:label="loc_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A1.000NotesDueJune22022Member_98864535C053560FAA74D3995D6900C5" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A718NotesDueJune12025Member" xlink:label="loc_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A718NotesDueJune12025Member_4F08CBBD2AC550039EFED18A3A7EDCF9" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.625NotesDueJune22026Member" xlink:label="loc_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A1.625NotesDueJune22026Member_03DB770DB61C54FC94741502E6FFACF7" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A2.125NotesDueJune32030Member" xlink:label="loc_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A2.125NotesDueJune32030Member_764ECE33E9A95CFAAC96875FF1DCECB8" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A625Notesdue2031Member" xlink:label="loc_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A625Notesdue2031Member_8B38D0AB14625667A0B71A4092866309" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A6.77NotesDueJanuary12036Member" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_F5F0F59D32E851C993DD62AA689FBAFB" xlink:type="arc" />
    <link:loc xlink:href="lly-20200423.xsd#lly_A1.700Notesdue2049Member" xlink:label="loc_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F0BA2018822E5A5E946A0E490420250A" xlink:to="loc_lly_A1.700Notesdue2049Member_43DB8BA5EB355CFDA7C76DF475E0AA3F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5638F035825852B9B6DAC281E95BB39A" xlink:to="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_DocumentType_DA58588C531E5F048340884A2707B0AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_DocumentPeriodEndDate_DC5958F28C505F659E2A82AC669C2A8F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityIncorporationStateCountryCode_F0EE04EC530157DAA03C456223951150" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityFileNumber_F7F0C969B0FB513F822FBDDCB47B48F7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityTaxIdentificationNumber_BE1F5A41AEB95AA3975563AF18362D1E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressAddressLine1_77CE674CA8E15342AF2ABB66FDD2CDCB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressCityOrTown_7CEB7ABA29FF5485AEB5A98D5F3FCC10" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressStateOrProvince_E4C75294F650576ABFEE67DE00BFDEA2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityAddressPostalZipCode_E993EC6C72415AC7B925D97B91D5B426" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_CityAreaCode_D197F340CB0D54D396CCFCB5AAB20153" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_LocalPhoneNumber_D6DEA295782C5104A9BA8F1F13F784D8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_WrittenCommunications_7DFA0DB240FE573F82A9E2BBD9023682" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_SolicitingMaterial_75B069E83E465BE58CD06B876A6B1089" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_PreCommencementTenderOffer_4FFDAB591712560BA8EE97B6D030C2BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_BE637EE8D14F53FC82AE406586C34749" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityEmergingGrowthCompany_8E9CE4CD34A85F0D98CA2E728E14343C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_Security12bTitle_F63120B3D75152F19C408C15CD983923" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_TradingSymbol_4EE63B5498985B15BC1FCD02D81298DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_SecurityExchangeName_B1AC86A9967A50F1839DD49C16FB3B08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityRegistrantName_A23B9DA2FB4254EC9F4B9952D6B960C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_EntityCentralIndexKey_028EBC3C28575817B1C97AD911EA31D3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5DB4F7D6461A5E808C3FFB5F4160367E" xlink:to="loc_dei_AmendmentFlag_39A9DA5ADD9F5168B7A8EC8AFB320C70" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logoa31.jpg
<TEXT>
begin 644 logoa31.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
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M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\Z_\ @X-@^*/CO]F'1O _PZ\&^)O$^F^(=0:]
M\1W&CV+WC6\%ILDAMGCC!DQ),4?<.GV7\*_12BN7'87ZSAY8=R<>96NCZ#A3
M/WD><8?-XTHU71ES*,KV;2T>C6L79I]&C^8W_@FU^Q-J7[7O[;WAOP#JUA?6
M^EV,W]J>)[:820S6UA!@R1.,^9'YA,< /\!G2OZ8M-T^WT;38;6WM_L]O;_N
MHH8Q\H':H_['M?M_VS[+;_:O)\CS]O[S9_<W]>M:E>=D>20RVG*,9<SD[MVM
MIT6[VU/L?%/Q0Q7&F,HXBI2]C3I0Y5#FYES-^]*]EJ[15K;104445[9^7!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>q12020earnings8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20200423"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20200423.xsd" xlink:type="simple"/>
    <context id="D2020Q1Apr23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q1Apr23"
      id="Fact-368D437F253A5BE29ED3BE40853484FE-wk-Fact-368D437F253A5BE29ED3BE40853484FE">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q1Apr23"
      id="Fact-C7E6AED84DA25D66959A6E9CA195E99D-wk-Fact-C7E6AED84DA25D66959A6E9CA195E99D">0000059478</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q1Apr23"
      id="d1581210e84-wk-Fact-3305AC51ADD657BB90DA8B1EAA6CA995">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q1Apr23"
      id="d1581210e110-wk-Fact-83B9855B698A565FBDA3F7987301AD4B">2020-04-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q1Apr23"
      id="d1581210e115-wk-Fact-A62E580AA82A5690B979710403D09FAF">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q1Apr23"
      id="d1581210e169-wk-Fact-2F8E3677682B58259BE1A209D95ADDC4">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q1Apr23"
      id="d1581210e179-wk-Fact-01A92A3FAD395760B6621B9D6CB81E33">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q1Apr23"
      id="d1581210e189-wk-Fact-BC7A4061C42F5519B51E72373256FBFE">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q1Apr23"
      id="d1581210e255-wk-Fact-41E881BD7E165ACDA59958CBAB5982E7">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q1Apr23"
      id="d1581210e260-wk-Fact-804EFB3A2C745FB1B7096B915848035A">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q1Apr23"
      id="d1581210e264-wk-Fact-9AA511DAEDE7528593D0B74D7BBA7444">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q1Apr23"
      id="d1581210e268-wk-Fact-8D3CCAE205005C7CAFF0607F0BDD0034">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q1Apr23"
      id="d1581210e280-wk-Fact-BE58DE83EE365303B14251909C342A15">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q1Apr23"
      id="d1581210e284-wk-Fact-8079DF23051055478657DF0607341332">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q1Apr23"
      id="d1581210e325-wk-Fact-69D5F792AA455B2D800C3A091B632657">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q1Apr23"
      id="d1581210e350-wk-Fact-8AD8F7A9A4AA545A965FCB34CD29B00B">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q1Apr23"
      id="d1581210e376-wk-Fact-2CDFF76871B1522994380231A0289A45">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q1Apr23"
      id="d1581210e402-wk-Fact-C0CEDD624684578A9B3C660780B93501">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q1Apr23"
      id="d1581210e422-wk-Fact-9E26649FEDA0510F9759552CAD0A3EB4">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember"
      id="d1581210e470-wk-Fact-5FB55072CAFB58D6B81125EDC4344223">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember"
      id="d1581210e475-wk-Fact-D94F262F9A3B5033A00FEA9602E4C019">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember"
      id="d1581210e480-wk-Fact-ECE184B819555081A016A8CF4383C6CC">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member"
      id="d1581210e486-wk-Fact-25323650B301534E8BA0C36606A1BF53">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member"
      id="d1581210e491-wk-Fact-C755C99D10655EA9818CEC1B99641F29">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.000NotesDueJune22022Member"
      id="d1581210e496-wk-Fact-350F2FE285B157B48229B119B7F7566C">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member"
      id="d1581210e502-wk-Fact-13B9D95012BF51E3A93ADEE09A911912">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member"
      id="d1581210e507-wk-Fact-3D85FB911A5E541C9E6961F54890FFF6">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A718NotesDueJune12025Member"
      id="d1581210e512-wk-Fact-1683AF99303050779B15AA62D1C26394">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member"
      id="d1581210e518-wk-Fact-AE50BFD9329557B2AC1C27590FEB98DA">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member"
      id="d1581210e523-wk-Fact-03B15E5D07F2594CB0053ACBA593F255">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.625NotesDueJune22026Member"
      id="d1581210e528-wk-Fact-7271AFDDA64A5E5C90CC0537550C6A39">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member"
      id="d1581210e534-wk-Fact-07D4DC44B1FC53D58B63CE95F7DBF32B">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member"
      id="d1581210e539-wk-Fact-3AC850390FA35A3392EA537405769EA3">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A2.125NotesDueJune32030Member"
      id="d1581210e544-wk-Fact-7E351F2D6D0855618AE4870845F05A19">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member"
      id="d1581210e550-wk-Fact-EE1882B7176559B9BC426C451014D115">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member"
      id="d1581210e555-wk-Fact-BC96DDB680DC5E0B91D9CD0C918060C8">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A625Notesdue2031Member"
      id="d1581210e560-wk-Fact-F881DF53D1975C518E63AF663A0CABBD">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member"
      id="d1581210e566-wk-Fact-A247AD634CEA599681FC9065C87062DD">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member"
      id="d1581210e571-wk-Fact-1BB19DA706A9549EB8F0877A24DA4A88">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A6.77NotesDueJanuary12036Member"
      id="d1581210e576-wk-Fact-2EAAE76CD681583385809063F5AE0CFE">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member"
      id="d1581210e582-wk-Fact-D11D264C96F45607ACAC0D97261A38CF">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member"
      id="d1581210e587-wk-Fact-028651DA85895049B663E28A1052C80B">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1Apr23_us-gaap_StatementClassOfStockAxis_lly_A1.700Notesdue2049Member"
      id="d1581210e592-wk-Fact-4B8702A425DA51A1B7BCB8F0904BA15D">NYSE</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6701821312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 23,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPM9I<S#_V/@JV+7PZRZZ+U!+ P04    " !80)=0F5R<(Q &  "<)P
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MP    !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( %A EU GZ(<.@@   +$    0              "  >D   !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 6$"74#2,"7'N    *P(  !$
M     ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 6$"74)E<
MG",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " !80)=0:?SXH]\#   -&   &               @ 'W
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 6$"74(8-
MN9^= @  > <  !0              ( !# T  'AL+W-H87)E9%-T<FEN9W,N
M>&UL4$L! A0#%     @ 6$"74+JA.8K7 0  ,@8   T              ( !
MVP\  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !80)=0+6VE:#H!   G @
M#P              @ '=$0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M6$"74/_ )@B]    A0(  !H              ( !1!,  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 6$"74 N/V ,A 0  5P0  !,
M             ( !.10  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H
,"@"  @  BQ4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "q12020earnings8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 9,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20200423_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20200423_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "q12020earnings8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20200423_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20200423_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20200423.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 35,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 7,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20200423",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "q12020earnings8-k.htm",
      "contextRef": "D2020Q1Apr23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "q12020earnings8-k.htm",
      "contextRef": "D2020Q1Apr23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 8,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "6.77% Notes Due January 1, 2036 [Member]",
        "label": "6.77% Notes Due January 1, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "7 1/8% Notes Due June 1, 2025 [Member]",
        "label": "7 1/8% Notes Due June 1, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20200423",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-20-000100-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-20-000100-xbrl.zip
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M]+:'EPTQ.TW^G:*\IN<WX.'%7U!+ P04    " !80)=0W_Y&NC8!  !E @
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M[%]]G.M#ZT"54$:%(;U;]JCS!5!+ P04    " !80)=00",E>B()  !Y1@
M%    &QL>2TR,#(P,#0R,U]D968N>&ULU5Q;4]M*$G[/K_!RGHWG?DDE.377
M+<[F5B&G<FI?5,(>0!59HB0YP+_?D0.$BVV(++'XQ192]TSW][5ZND<R;_Z\
MF.>C'Z&JL[)XNP?WP=XH%--REA4G;_?^/ARK0W-PL/?GNU=O_C4>_Z._O!_9
M<KJ8AZ(9F2JD39B-SK/F=/1M%NKOH^.JG(^^E=7W[$<Z'O]4&BT/\JSX_KK]
M.$KK,+JHL]?U]#3,T_?E-&V6<Y\VS=GKR>3\_'S_XJC*]\OJ9(( P),;K;42
M[5_C:[%Q>VH,T1C#_8MZMC>*'A;U<NXG3'(MWEZ=-3<*MX7IY.?%&]$'0Y_C
MI2R44DZ65V]$ZVR58!P43O[Y\/YP"<DX*^HF+:9A[]VKT>@G<E69AR_A>-1^
M__WEX,X@>9;GE_O3<CYIKTY,&>G\G)ZTKBQU3ZMP_'8ORD1DXDP$X1:7/Q[(
M-9=GX>U>G<W/\GAN\FORM)I>SW]U>-N$&VBRHIG,LOGD2F:2YOE=$]: ?XUG
M2QQ=FG9+LV^CXG$HVF ?S\)QNLB;CB:N'6= @\MYFA7;VWMGF-[-78X^GH?Y
M4:BZVKIJC+X-/8WC5=/%41C?0-/1W TCK34Z!DU69&WB>Q__O))N[?JM._OG
M\.&B"<4LS);IXGJ"O)P^\*:^QJ,.T_V3\L=D%K+H$I3MP;@]& -XE3;_B*>2
MZU1_4!R7U3R],C<<-&%>7]N0IT<AC^FEG":/J234:N*Y981!19T PF#O-?4$
M,H 9=W?]RMNEH:RN<!O:L:_I41Z>[M12/*$,"P\P%8@*BK34S"J#!'22:HVE
M>HI#OT)!5=-16<U"%1?B:\VK</VM;-NNPGTS4O:.1C0\GEC>2Z^G>5F'V=N]
MIEJ$7R?+HHFQ[?+0SA9OHW#2'CPA'JYQ.D[KHR58BWI\DJ9G/V,BY$U]?>9^
M<%R=3@Z;6-JTLYD\K>M/QX=-.?VN+K)58?^H3B*@P8ICZ 0BE'DG'""$"ZXL
M\L)X_XQALB%9/1HVO\ER.0P\R[AYAA"X;::]LV:NX/ZA<.(D-Q(*R"$2FDC"
MB :0 &FIX 19G'"DN)7$0L  !8 )X;'$# @?85!4/F-4K*UF?L5$CS26SXW=
MKH2,!UK%H85 R$4O7'1< 4=DK-D!HN YEY-U]>+_*2!^#YEGX[N<S\MB::[Z
M<*=:7<7W ^%$86T49@AKS"G!7DH3$ZJBUC(!$&3/R?>JFOLAV=M0<Y_E;?%X
MG.4'/6\\D2BX#P#X6#:AMHOPUZ((*,J@M?P]JI-((1BAF!H0/QCP2G%BL934
M,@F H9UI1"^8QKYAZ<HFA^*V ;"U=C.7ZS42XF,%K+5%RM"XK&#IO+-0J)C&
MG#6^^Y*,7SJ3O8'2_:YDB-X/)?;87;E>)P'8:LZ!U0P:2KR1A!-( 7+,>V4\
M[\PE>>E<]@A+5S;1/KQK D8 @\UL;M))."/..(R=5)*:F$N,9()3[Z$USFC1
MF4WZTMGL$9:N;%Z'TVP1XMQP,XTKA1.AL;! :4CB=<:X II#%4MZ)!C#H'MF
M92^=OS[PZ$S</N<WH9,6B[2ZC)D=/Y)6-VLEGGK@J;08.4&AD1+'^@PIQ83T
M6GG=F4K^XJGL$YCN"R6_JKF6$47D8VOD2O&$Q'5 Z.BYQC1F#JNXX<QZPJD#
M2N'N>U+BI;/8#R)/ZS$[[TQ_C9,\LAO=BB1644&%,#2VV3'\B, $"$$4XH#K
MF%]>3@LYZ%YT!RP&)O!SJ+)RYHJ939O'F+PCFUA#)14>14< ]8Q*AY2(Q3=C
ML1U6HON=V7L[.2BEVX R$+>N:++F\J"8EM5962U]7>Y^F7)1--6E*6?KF'Z"
M9DQFSH%8SE$,(.56*8 -H0PA+"F,)?K+:3X'X;U_B :- I_EX>-BS<J[2BSQ
MW(-8GDL-(A00^[AH>6VMT81K(EY20SH@OYWQ&)3,K^G%P2PZFQUG/U]'>@*S
M:W02[:"GBD#EM*2Q;I"<4H:5AP(S9.&3'G(_3Z<Z(,W]@#,HYVHVJT)=7WVU
M3L.-?*^03S@WCG%BE'"08H*41TIKQKRUR,1(?CE=[8!<;P_,<_!LXN&GZFMY
MONJ9W ;I)'JBN8I]AO2>$D%CZ%(EA:4>>V-@]V6Y]W9W>(X[P_(<#"^KA4_5
MYZK\D;5O3SZ!YGLJB2.&4R1)+# !Y4QI[V(86P> ]M8IU)GKWIOBX;G>#IOG
M(/QS63=I_M_L[-'">Y5"XJ3$SC##$8%4&:XEHE;&+VBI)JC[TU>Y>V1O@\Q
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M%_@ZO/KYN_H[X:^;X3S_^;O_ %!+ P04    " !80)=0/=WS3O\(   L3P
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MQA&!"1""*,0!UW$#'$<OJ;^U6T.&5^ X\.+_N'MNT^8Y%CR23:RAD@J/HB.
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M6Z<2Y0)!&!G5S1>SR3A+)%4W"K7$2DI[J*2(QIQRG,2!Q+/F1 G8L:N)'.R
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M@HE% OR(WRPC'0^&3/!XR1T] >_&K_<&P=8/G+H_HJX+?'+CL7[\$G%6]_/
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MDBU3(%EPM6% * @(1G^; LF"%T@>+E&Q\=Z*[@6#(VR#+$'%T@05^HDXWQ3
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MOFQ=3_CN<ED>4ZZQ34+7VD5NK06YG6')J>O'[\AK6V==N]WQ%*Q/>I [^1M
MZR'$<J49.AK@E[SY7JB]AO/?8##X%:O2;F<=FMM(C'DM=M""$G772Q[#\QW<
MQ7B+5EVHZ<OIUH%\KEM:]P F*K]I&FNHF7.1PEG/T#ABU=+8LO\J0C=QGCW6
M7,3=A$-RD9FW48 E7_2*G\E=YNM>;CN)HSP\4 !1+TC1VR%&CM3.V99<O?XB
M$O!3>#PJU82$<Q^(</7:JMAVMVHZ+9R/)C72<#AIZ+2[5=/.MMRRD)_7D#?W
M-6HY%L:?N;_PM\2G7FB.MQ^>ZUK=9K5C=%Z1=%XY&*M=KQG&*A9C79 QO6[F
M.2CLS*WIK<?]F)99V31;M:H9Y%<H95,.QFITNU738ZQ0C'5!5LS*\ZSTF1NQ
M+]2+OY5:U33J5=,ELU"JIAR,93=MPUC%8JP+LF'MEK%A4VG-Q./!:=.:P)?M
MQJOR9S;K5M/LYA1+[96#L>QNVS!6L1CK@NRI,:?C&]]020<>75:Q6QIE4Z_5
MC;(IEK(I!V/93<L4?A6+L2[(BMF6,6/CTR>AB%EH@L*C\%W;-EJO6%JO'(Q5
MM^SJ+B<_#&,9<YI#N8M5-_4NXQO_3H7+:>"PT]K4Z]X%U(_:K;;97"J6WBL)
M8]7JU99AK"(QU@49U+J)3\<WWHW@]V^EKA^UZ]WJ+F?WC;(Q5FQ]!5^W4S5#
M_@K%6!=DQ4R6==J*^3WJ38Y!G"8FO)@\JU4S>=9BZ;UR,);5:IB3/L5BK$LR
MJ!UC4+,;_\G$-Q;PL-3:IM,Q<6&QM$U)&*MFVBX5C+$NR(RUS;G"\8T?O<3G
M-(A+K6WJIK%5P;1-.1BK8YM@K%A\=4E6S#1,&]]X[P_@N:OZJY9#V;0;)A8K
MEK(I!U]9#=/BI5A\=4%&[,,OQH9E'5Y&#Z-2AV'-MLGY%$O1E(.ONN;D0;'8
MRMBO2[1?;^@?DON\S)K&:IN>OL52->7@JS__J6-;]B[:U+"6L6+%LF+',&(K
M)G1WH\,.Z-YFU-LQ!.!X:%\0JF:%#:K'5>PGHD2!]?L1I[I^"6/J9</:R^QC
M-BN=9M>$+\7R,<O"6K6N;3:1BL5:1;-RATS+-/>JA#CJ=-Y]XIM.@;S?4TPO
M/QU9#"D,AQ@..1]2Y!%_'9I2T_9I+%16;954X>G:0_#)[D[7:K.<WICO^-%=
MP= +D(Y4)3QPO,1EDKP/) XC(#]S&8FY4USG0)[Y[EK[D6?<,VQ"H)^\T1/U
M>WS?%^1Q8KR2)ZZ?1\'O@.ZH"(CE@U>%T, E7P0O&5YZO?[]Z032^>$7HG;E
MK%<D"&/B,QJ %NTGWBOR(?%[3$CBTY'Z#10L<1-&XI"(, E0VZY2]S_$M.>Q
M\??SZ,R0M@.D/=QN_6)@K/Y1WTX^KH+-GH7-84',Q&'B]7U!F+I_QGQBM86Z
MGP=@]/7GZ1<$H0"+,6-AK9JVGFH1B<,\+_WUKU=@MO$S&'$G^[P$[2_<!\7Z
M@3V23Z%/%U( /A4#'FCP:!*'V1?:=*MO'KD;#^%J0#[U<<!U\&@DV<OLCP6F
MN5KB9ERM#I*G7K'FJCG%X(/KY+'U#DIG$P?%:DS<-T7SB?/64O^M6-/L!8LL
M,0-3VSZ$5[?U[=:R8T-;:XC:\:10_SL4$[(/V$U/,/KUAO;AK2^I]TA'\JH\
M>L. 4! 0C (_A@)_+CQ/E>\1,Q5VXQ@!^#)]N\H?.KJ;II[K,B<4-.9A\!*<
M2R;P[?#(]SZP:DS"/KG[^,_W;V^L+@D#\HX+&=_\(Z$"A(G8-;NV?&_S-$[G
MER%(70B !R/"9,Q]&H,XQ4,:$Z&AA/ 3/C/21SS('RD>@*1"I1\*\+KA9OB"
MQY) X.XF#OSQ2"7ITP>@4\\;$:Y(PUS2&V$X"U9*P@<GD<"1\+1>,@)V)!&-
MX=F!5+$3?."@1.")3#J"1TAN$@L6N!) DXD7XRU]$?H*O#') 167^=S12$Q>
MEJ$#$- (P'Q2N )LW]G-&@%B>?B"QU!X+H@KJZ1A-[YD_OK:Y/J4.+]5/U<5
MU'.73CTY3&()SYU</DWZ'O,XP)=2'B_) ,<WJ,LS^!7&$VP%O$OP:1*K90A%
MW <U$>*ZN)SV&"ZKSUP.NI3)"GGD\7"\X.[X;1*OG\.A/<$!XJGO.I./N/@\
M3=J,%WX)%>JS3VC,/N&+@ <X/!Y5M5Z8(0SU9#C/F+/DP"?@).8U'+>P?C/@
MV,WL8[4($KFYN3Z5GALOV.G!O'JMU>L?T^IU+,,3UAJS"S+)O@T7O[.JMMTE
M/<TT^SX-,T43:0?QV_>!(%X1$^B\[?ND/_^I;K]2DBA D)3*0-6T[V.5)<D%
MMBEKM._S[)K5W?<9U5G5-+$]Q5G2"JJ\O06@:W>K8ZVY/TBNX$"Q6=_@(?02
M'ZPP\%[,J>>AA]&7+,:KP#.%18<+/7B,BS;08;(ZD?:_R.67S%AK^)U-F<\T
M73@$G04W.@"DT/9#L)XR/6C7G"$-!OHYD@U\=$]\_K0<R/1)'I?Q&,+4\5OT
M!7)12W:W6^WFMRJ%54O;,PS2.0DRYX"ES@%B!>X#F*F L">]MD2,%WLYEQ7!
MYA7?14CW]DX/I!IF5V:K9=?V%Z>)PY3MR68F;-]G WMH\<R%</L^I&D<H],X
M1OEX':UNL]K)R[Y-C/&T4U N?K>L8KF-]6ZGVLK=;9SX<*M<P\RYFW+?)BD%
M3"!,^W@NETZ8!/'V'M^\+[+&W]L7^?&K"L%G3;)@Z,V^M=GV,/O6F_#IOOO6
MRPYYF'WK(ND- T)!0# *W.Q;7^B^]=7K0D4"=K==M?.+!*;2N ?.#)K\WT;Y
MOUN/^S$]/8PF_;=5^D\O6V[9OV)%J99MTG_GG/YKMFI5*[_TW\Q6;<DX/;=$
M=TYY/[M1M;7S=%23CQD\A0$E'I/P*##F,5"EDFW.+FPA7TC"KI.K)LS%(:SG
MF-O?QR%<GD!>R4C&?SQ,B1E6])T>1.,^;N4^ZCK,<MK4=LMXC^?L/38:]6HS
M5Q^DU"YDIVA;QW8[Y^5;5T6VK>.X6$>XW5;SQ3B>K8UC\)5)V,K>),F#'RVK
M5:T5VE\UKNG!2AOQP,OI@33.Z;:EC>J@4CGMM?%.S]H[K5O-:MOD-H_)Z#EM
M9%J-_)+2.9V$6>*#3M4N7HRO6; DN%6S<CTSI==XW\C%[(H?T75\0R4=>%2<
M'DKC.V[E.V8+=WR;NJ86*0<5:>>6Y3%NXTG<QEK]_-W&P[*XM;'#N#KC5*!=
MTEJU<8BLDSF_8<I_S?F-G?ATW_,;=7-^H^!ZPX!0$!", C?G-_)3U6=V?F-U
M:O!B,GKUW.H6\PF_VO5J_6@U"3EEZB:Y#"[5$_':>-)Q3[58;[^2!%ZDQP^H
M8/Y-R(8"1!<BZ/?PKP<\[U?)SQRA$0S;#<(=$AXBU0,E]; J@HXPZXQ]V5V5
MK5SV%%T5$8ZH%_-TYUKU%4R[&*K6B1K"@0@E/@L5*2:U5;,WO!X#\@HVA8R8
M$P/]O%'UN96X QGM"5Z1-) W"ZMA+?*LR6RNRVR^@Y5BJT=VF+QF,?.:>ME*
MVNW'JIODYCDG-^VVG5^R*^?D9K$X/3=&SVFGT[8/TQUR^6[W0NWE:I]H27='
M[10=S($N%J/8^;:&S859&MUJYPAGP\8+\>Q&^8KNHD5P;HKA",YUC7]"KUN2
M?B)B%*Z4O$!O!$@7/:=^!@0(-.W=CM*(3V Q1X^=N*, 7NW(A8;J^ &61:@.
M\P,6 $".^J''0\D!6BHF#U(=Q3U80.S:CG=Z&#' C1'%M<58R$LD?\".T.F+
MXB$7[FQ;>ZL[#46%_)T"HNJ=/OT=L+E/1!@Q^ J8["N+3?7#9C'">*#=Z<&<
MX>!QQ#OQBR>S]S*'P4U$QE,E=?OVCRP43/ET,FZU\_0@<NYD7#=5$R<*+ [6
M8+UH)^:M1N, G3*WRQWG,RH!8H'B]B1OMH_1D[PZ94\.D73-Q&&21!7,80"-
MB_.' A:GZ5AXYP00=&?F<JSC'\?@[))Q-4[0.B?H;@1W?C.=D<[!GYG.E*;K
MEN\<&;O>K=9RCGUSUI"F0K0@ODXN#-?I5JUB\QO$WJ86T92RF%K$D]0B-DPM
M8L'UA@&A(" 8!6YJ$2^V%C&WI,DF?4\.GJ)J=*O=8GO%=FZM:S<D>1'R$^>0
MS/%[U#-]KH\03^>=S=$+5](>&?;&==*'/7MILCW'+IFS<CP?>H@$E&5MOJUU
M6-Y,*SP*QY!%.,QQX*8#W6)HIUSV:;N=/-M6YS4(>SC9&\=MN[0D:ZG[O,P=
M7+8SB5N(J"QQSU"%3+JRZ]^ BHSQ-$E /D>4!\9UW,AU_"<3WUC S9&)<W,=
MLX4KJ>O8-D-2SMH#M#J=_/K2'L0#M+MYMC#)N[0OQQ.F1<AM-7,=N)PSL;]K
MV/EU+S+J9@>83 9P3S?N(]"*TXFV,&Y<H=VX;+GT01**!\ FGEUFYO+0;%:]
M>[#&;'DE8NKYP7?H&N).@5V&=KYGZHP)RZGFN@@JN?@&[-X?P!OCT>FA++@!
M0P-4(1FY#FY VHT\QXOD[;BW\TMZKE!Z_1"/D\Z?RSR$)6RU\[.$!PB1\AN3
MO16E\Q]),]>4'OZ<#$928SDVFHN4GIO)S[EHY1R"%G5?*=-AQ0WL3)FWJ1(T
M9=Z;\.F^9=Y-4^9=<+UA0"@("$:!FS+O_%3U695YKYW//7H8%2+I/=7'Y2^2
M*+"6]6Q1[C29<X5SVF)K%S@Y^1TX_+GE$;8,U?5B;-7PX'T0@#P"=&]XZ(4#
M[L@*?.=4,4"\&_* SG<_B,.8>I/V!OJ5JMLLQ*'ZTDF#A(I^R4)7VO%;-^D[
MJ]\,^,]WN\U HYX,EW5GH&L?BZ_6T&MD,APRV*I:D9BLYD;JZ0W] WN#G1[(
M25)SJ0:JD!32PV](Y9BR4UFXG+>CFGF643X.N3=%OH-L2MDYEMD4@4]-2L9X
M]"8E<[*43*O<*1E* NK#9?+MN]:;6L=NU6K-=K-1;W7:;QK-^FVG:=_>-^_>
MO$$.HV53.0:$@H!@=+_)YIALSD*XI)(A[R"\#AP.X?1/"7<W[]/;;ARKT_00
M_/8D<E64Y #+48B;F<=T,)\>35*H],>H#%)4L!$BG<3N/2JYWFH&PQ0&-S_=
MWOZ:?AEC\-[WF!,3X+LA!.(!F#9\QU]DVNM:$5 ??PHCIND)[X(_^Z@GLNZ*
MN@U]"F@\(C(1(@2R9SDIW6]<;W@G^BE9:F#2L1X_W7W\Y_NW-U:7 !5<YG.G
M2OZ'C:8@(U3*Q(\T6#*)5*(A?4M&L#$E>.!XB<M>SJYN;FJ,+(K9,I72Z&C9
M5=*C)6@CW0*ZX6H]+\ZQT*R6:>BW[IX!Z]AV:YD"6 ?PJV<@/JST3&HVG$2"
M'F6"])(1LD=$8S"3@18$^,"1E2+!I".X8B82"Q:XF,62(8A3G&7]Q@P9#VE,
M'IE@2C($/,"!:](2B!4Y5XB9B0>VC'DCTM-1ND#H4'6G*<)$Z.PGWO"LMC6<
M6U;.%<Q-',6''-O8/H)C "&&8M8E3*H8*X( ).,_"<8N<!<8<'[ @)\X0_Q1
M=_4W[':1[/8W1KUXZ%#09!0;&O-X5$DM)6I*]!'&2D\P3ZG"3&,^<(F>1[8?
MP@6)AB/)06$&LJ+94L%,_! >[WBA1-6G+A]RT,@"B4 \T(.>G./=(?7Z8T5(
M#&M>(FN^']OO).8>_S9V%#/^HWUP.UW:XZHP.1+A !ZHC7I6; E<)=E N8H^
M?\I*,2>>@5*&2<#\R O5YIAFVX -J.[NG7FDZD(LZ(3E,*KR(OGQ#MZE-%8L
M,,)B@0@]3_$,AF-/H-%08\H8-"<#_0<QVR-#%8A<R&,^9E\PZ,29>5:F+7%"
MD,_6JD)@;L-]E\A][X,')N.,W19L,K .H\(95DC,-".B&DQ#8LU=./R-X[Y@
M/(1P?# ,DWA98?0B0Q5H7^X$<+Q1AB+4,OF5C69R#D!#!,4EM =A7&6ZTD-E
M;:C[.\2>\#LL3@"K(C%90N00_2U,HRC''"Q2$#YB3)A*OE!CBT'FOVM5]>_P
M1Z.V,I>#M?S99=WTLMGLCMEI-=GVLF7;S4[K=CNM[7+OM)9 ;Q@0"@*"4>!F
MN[3 VZ7V1F[:&3&Q9I]NMVJUK(;=;+9;3:O;M??CU_JS_-IJ3-AU@9<[F_VV
M,9OGP\8I0=1#ID2EIOY;X<2D/ZZ7@$-R_=J(>J7XIV#G2K=-*+/60.P5 JF/
MCUK*>J'GOIIM[[,@]$>%Y'YJBW^;-7Q.BQ]B&5._?1_^/RIMOR=W*B%-^B+T
MR70+F'G;L'?$DY,F64FL7',"R]AP,5%RG:4\7NQ7<+[D;3_*)%JCFQ:L[N2)
M47SU^IH"1/"$^<!EK;SDNH@GY.G9W-3)*/",1CBE:F]^C^2QN]_O).S(?Z>7
M]!D(+'O.=;RQYG(;>V8(;WTLX)KL]/$@!K7)T>FD4K)X*\.4'P&/Q417KZOU
M95F:H[J6FTG2,=W'HLK*D67#^2/A>/[T_:^?_DS]Z-7;?8]?[6G\>CL8O[.4
MR9J122.3RV42C9(J$>$"MV;59/A8)$ZL3^#CYEP8#]&3A> *JP:<(5: RI4A
M7WZP+4FHEU TEQT?,Z)Y+G'D,:5UPU@SVS=_L4-$,YL#J0,QW#!!Y_4R<EFS
M90@F(EP@D&6IB-!J[!81GB+3MF=ZJ+,C!?5]'Q*_QP3V!!F1((P) )F5<&8'
MBC;)G>8*4\X9HQVAT,K_4U8*M*2Z*&W-G5;"3A*/!.!U$ETTULM*FQ8N6E:N
MA#^F-63HVXQ/@*TI+BKH(LQ'+GLMPGM]K Q/Z &)\"!1UF8'"[QH%K7QX"82
MH<.D'-?JZ1-P6/X>1JJP+Q8TD-31I66J3OXSC\7H25UXV[MCG@<T/SJU=UE?
MR]I5=UH[>:]'U8T%W$DKTB[,B5W?;<J9#ENS6Y02UNFSQ#)6YW) C3L\4HVG
M50UJUC.HQ^)'Q@+RG5VOMDE/]_G11:8VMN1.OYGTIQZ(\!$4%9?ID_5)85!X
M8*1[;*J%=CJ+49D1+*--;P2EB(?=Y-2AHR\B\0 Z/(GTA7KQ-VP6)>G HZ)"
M_DZ%J_JF5<8#Z2KD;@3X?Z.3,2>3?O631E.(@VHT-E.:C^6VR-]9QOD?;S[=
M__M_;R?-R]+SS%&(9Y8Q@O=H$NB#<SJRQW)^G[EX,H3)9729H\BZQN'Z5K0;
M8[*HDZ9#^L#@(HG&19V=9D] +*F.:RU[I6K%ML%[*;X96"480)#B\@&/ 9U8
M-RX'RX2G%-C,N<%T.2<MTGNCF0;F'AMPJ9V+[)"-.EG^"Q((O8A?L27>6]U
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M?0R%YU;)OW"-!*X=M@)WB1]B<#I$GB5H0!-X%1V$>B@O&"B<&N+S.)W=HB!
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MD4<T=@[SO/3%?[VJ7:G/,J).]CE]U2K8TK=_X3Z3Y -[))]"GP:OR.+[9Y-
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MN06.&9 0GB/@8; HLH(/'2F]/&1>-+F8L ?J);#V2[& QX2XIA,D%-PCXM"
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MC+08TAO2&](;TI>?]$OS?N6SU^>0VC.#MPLF&T8M&=)?(NFO&Y95[93+ )B
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M+3(P,C P-#(S7V-A;"YX;6Q02P$"% ,4    " !80)=00",E>B()  !Y1@
M%               @ &S!0  ;&QY+3(P,C P-#(S7V1E9BYX;6Q02P$"% ,4
M    " !80)=0N]+_WS(1  !*HP  %               @ $'#P  ;&QY+3(P
M,C P-#(S7VQA8BYX;6Q02P$"% ,4    " !80)=0/=WS3O\(   L3P  %
M            @ %K(   ;&QY+3(P,C P-#(S7W!R92YX;6Q02P$"% ,4
M" !80)=0&%V8/SD=   U  $ %0              @ &<*0  <3$R,#(P96%R
M;FEN9W,X+6LN:'1M4$L! A0#%     @ 6$"74+S#0+>19   $4 ' !X
M         ( !"$<  '$Q,C!L:6QL>7-A;&5S86YD96%R;FEN9W-P+FAT;5!+
4!08     !P ' -4!  #5JP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>9</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>8</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="q12020earnings8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="q12020earnings8-k.htm">q12020earnings8-k.htm</File>
    <File>lly-20200423.xsd</File>
    <File>lly-20200423_cal.xml</File>
    <File>lly-20200423_def.xml</File>
    <File>lly-20200423_lab.xml</File>
    <File>lly-20200423_pre.xml</File>
    <File>q120lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
